Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery

Author(s): Jooste, EH; Scholl, R; Wu, Y-H; Jaquiss, RDB; Lodge, AJ; Ames, WA; Homi, HM; Machovec, KA; Greene, NH; Donahue, BS; Shah, N; Benkwitz, C | Abstract: To determine whether precardiopulmonary bypass (CPB) normalization of antithrombin levels in infants to 100% improves heparin sensitivity and anticoagulation during CPB and has beneficial effects into the postoperative period.Randomized, double-blinded, placebo-controlled prospective study.Multicenter study performed in 2 academic hospitals.The study comprised 40 infants younger than 7 months with preoperative antithrombin levels l70% undergoing CPB surgery.Antithrombin levels were increased with exogenous antithrombin to 100% functional level intraoperatively before surgical incision.Demographics, clinical variables, and blood samples were collected up to postoperative day 4. Higher first post-heparin activated clotting times (sec) were observed in the antithrombin group despite similar initial heparin dosing. There was an increase in heparin sensitivity in the antithrombin group. There was significantly lower 24-hour chest tube output (mL/kg) in the antithrombin group and lower overall blood product unit exposures in the antithrombin group as a whole. Functional antithrombin levels (%) were significantly higher in the treatment group versus placebo group until postoperative day 2. D-dimer was significantly lower in the antithrombin group than in the placebo group on postoperative day 4.Supplementation of antithrombin in infants with low antithrombin levels improves heparin sensitivity and anticoagulation during CPB without increased rates of bleeding or adverse events. Beneficial effects may be seen into the postoperative period, reflected by significantly less postoperative bleeding and exposure to blood products and reduced generation of D-dimers.